R. Scalamogna

Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors

Vanesa Gregorc, Filippo de Braud, Tommaso Martino De Pas et al. · Clinical Cancer Research · 2011 · 54 citations

Medicine, Oncology, Pharmacology +17

Bedside Transfusion Errors: Analysis of 2 Years' Use of a System to Monitor and Prevent Transfusion Errors

F. Mercuriali, G. Inghilleri, M.T. Colotti et al. · Vox Sanguinis · 1996 · 45 citations

Medicine, Hematology, Clinical Decision Support +15

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience

Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia et al. · Therapeutic Advances in Medical Oncology · 2022 · 30 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer

Matteo Clavarezza, Monica Turazza, Enrico Aitini et al. · The Breast · 2013 · 14 citations · Full text

Medicine, Oncology, Pharmacology +17

UFT as Maintenance Therapy in Patients with Advanced Colorectal Cancer Responsive to the FOLFOX4 Regimen

R. Scalamogna, Silvia Brugnatelli, Carmine Tinelli et al. · Oncology · 2007 · 11 citations

Medicine, Oncology, Pharmacotherapy +17